Stockreport

Pulse Biosciences targets CE Mark submission in 2026 as nPulse platform advances clinical milestones [Seeking Alpha]

Pulse Biosciences, Inc  (PLSE) 
Last pulse biosciences, inc earnings: 11/7 03:42 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.pulsebiosciences.com
PDF CEO Paul LaViolette stated that Pulse Biosciences is “creating a pulsed field ablation platform to completely shift how physicians treat disease” by advancing nanosecon [Read more]